Ultragenyx Announces First Patients Dosed in Phase 3 Program Evaluating Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta (OI)

Source: Nasdaq GlobeNewswire / 06 Jul 2023 08:00:01   America/New_York